Evidence map›Paper›PMID 33941036›Full record

ArticlePharmaceutical biology2021

Establishment of an anti-inflammation-based bioassay for the quality control of the 13-component TCM formula (Lianhua Qingwen).

Shuaishuai Chen, Xiaojuan Yang, Ziying Wei, Yanru Zhang, Ying Huang, Zhuo Shi, Ziteng Zhang, Jiabo Wang, Haizhu Zhang, Jianli Ma and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Quality Control ofMolecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Shuaishuai ChenSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xiaojuan YangChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Ziying WeiChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Yanru ZhangChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Ying HuangChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Zhuo ShiChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Ziteng ZhangChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Jiabo WangChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Haizhu ZhangCollege of Pharmacy and Chemistry, Dali University, Dali, China.
Jianli MaDepartment of Pharmacy, The Fourth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Xiaohe XiaoChina Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Ming NiuDepartment of Hematology, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNChinese People's Liberation Army · CNDali University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextOwing to the complexity of chemical ingredients in traditional Chinese medicine (TCM), it is difficult to maintain quality and efficacy by relying only on chemical markers.

objectiveLianhua Qingwen capsule (LHQW) was selected as an example to discuss the feasibility of a bioassay for quality control. MATERIALS AND

methodsNetwork pharmacology was used to screen potential targets in LHQW with respect to its anti-inflammatory effects. An

resultsThe tumor necrosis factor/interleukin-6 (TNF/IL-6) pathway via macrophage was selected as the potential target of LHQW. The IC

conclusionsA well-established bioassay may have promising ability to reveal the variance in quality of TCM.

Indexed as

Quality ControlAnimalsAnti-Inflammatory AgentsBiological AssayDose-Response Relationship, DrugDrug CompoundingDrugs, Chinese HerbalInflammation MediatorsMiceRAW 264.7 CellsAnti-Inflammatory AgentsDrugs, Chinese HerbalInflammation MediatorslianhuaqingwenBiopotencyinterleukin-6macrophagenetwork pharmacologyquality variation

Identifiers

PMID33941036
PMCPMC8110188
OpenAlexW3159564176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.